Читать книгу 40 Years of Continuous Renal Replacement Therapy - Группа авторов - Страница 38
References
Оглавление1Honore PM (Editor-in-Chief): Renal replacement in critical care; in Honore PM, Joannes-Olivier O, Spapen HD, Bihorac A (eds): Textbook 269 pages. Lambert Academic Publishing release in February, 2016.
2Glazer S, Saint L, Shenoy S: How to prolong the patency of vascular access. Contrib Nephrol 2015;184:143–152.
3Granata A, D’Intini V, Bellomo R, Ronco C: Vascular access for acute extracorporeal renal replacement therapies. Contrib Nephrol 2004;142:159–177.
4Parienti JJ, Mégarbane B, Fischer MO, Lautrette A, Gazui N, Marin N, Hanouz JL, Ramakers M, Daubin C, Mira JP, Charbonneau P, du Cheyron D; Cathedia Study Group: Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med 2010;34:1118–1125.
5Morgan D, Ho K, Murray C, Davies H, Louw J: A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. Am J Kidney Dis 2012;60:272–279.
6Lameire N, Kellum JA; KDIGO AKI Guideline Work Group: Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (part II). Crit Care 2013;17:205.
7Canaud B, Formet C, Raynal N, Amigues L, Klouche K, Leray-Moragues H, Béraud JJ: Vascular access for extracorporeal renal replacement therapy in the intensive care unit. Contrib Nephrol 2004;144:291–307.
8Parienti JJ, Thirion M, Mégarbane B, Souweine B, Ouchikhe A, Polito A, Forel JM, Marqué S, Misset B, Airapetian N, Daurel C, Mira JP, Ramakers M, du Cheyron D, Le Coutour X, Daubin C, Charbonneau P; Members of the Cathedia Study Group: Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008;299:2413–2422.
9Joannidis M, Oudemans-van Straaten HM: Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007;11:218.
10Schetz M: Vascular access for HD and CRRT. Contrib Nephrol 2007;156:275–286.
11Baldwin I, Bellomo R: Relationship between blood flow, access catheter and circuit failure during CRRT: a practical review. Contrib Nephrol 2004;144:203–213.
12Parienti JJ, Deryckère S, Mégarbane B, Valette X, Seguin A, Sauneuf B, Mira JP, Souweine B, Cattoir V, Daubin C, du Cheyron D; Cathedia Study Group: Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients. Antimicrob Agents Chemother 2014;58:5666–5672.
13Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990;38:976–981.
14Mehta RL, McDonald BR, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months. Contrib Nephrol 1991;93:210–214.
15Jacobs R, Honoré PM, Bagshaw SM, Diltoer M, Spapen HD: Citrate formulation determines filter lifespan during continuous veno-venous hemofiltration: a prospective cohort study. Blood Purif 2015;40:194–202.
16Gainza FJ, Quintanilla N, Pijoan JI, Delgado S, Urbizu JM, Lampreabe I: Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis. J Nephrol 2006;19:648–655.
17Jacobs R, Honore PM, Hendrickx I, Spapen HD: Regional citrate anticoagulation for continuous renal replacement therapy: all citrates are not created equal! Blood Purif 2016;42:219–220.
18Oudemans-van Straaten HM, Ostermann M: Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 2012;16:249.
19Jacobs R, Honore PM, Spapen HD: Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy! Crit Care 2015;19:50.
20Oudemans-van Straaten HM, Fiaccadori E, Baldwin I: Anticoagulation for renal replacement therapy: different methods to improve safety. Contrib Nephrol 2010;165:251–262.
21Ricci D, Panicali L, Facchini MG, Mancini E: Citrate anticoagulation during continuous renal replacement therapy. Contrib Nephrol 2017;190:19–30.
22Schetz M: Anticoagulation in continuous renal replacement therapy. Contrib Nephrol 2001;132:283–303.
23Jacobs R, Honore PM, Diltoer M, Spapen HD: Chloride content of solutions used for regional citrate anticoagulation might be responsible for blunting correction of metabolic acidosis during continuous veno-venous hemofiltration. BMC Nephrol 2016;17:119.
24Vargas Hein O, Kox WJ, Spies C: Anticoagulation in continuous renal replacement therapy. Contrib Nephrol 2004;144:308–316.
25Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD: Metabolic and coagulation effects of citrate: down to the last detail! Crit Care 2015;19:433.
Prof. Patrick M. Honore, MD, PhD, FCCM
Professor of Medicine, Deputy Chairman of ICU Department
Director of ICU Research Unit
Centre Hospitalier Universitaire Brugmann
Place Van GehuchtenPlein, BE–4-1020 Brussels (Belgium)
